VIR vs. RLAY, REPL, ALLO, BEAM, FATE, CRSP, IMVT, IBRX, ACLX, and DNLI
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Relay Therapeutics (RLAY), Replimune Group (REPL), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), CRISPR Therapeutics (CRSP), Immunovant (IMVT), ImmunityBio (IBRX), Arcellx (ACLX), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Relay Therapeutics presently has a consensus price target of $21.60, indicating a potential upside of 141.61%. Vir Biotechnology has a consensus price target of $34.00, indicating a potential upside of 217.76%. Given Relay Therapeutics' higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Relay Therapeutics.
Relay Therapeutics has a net margin of 0.00% compared to Relay Therapeutics' net margin of -677.69%. Relay Therapeutics' return on equity of -32.58% beat Vir Biotechnology's return on equity.
Relay Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.
Relay Therapeutics received 1 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 63.24% of users gave Relay Therapeutics an outperform vote while only 49.41% of users gave Vir Biotechnology an outperform vote.
In the previous week, Relay Therapeutics had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for Relay Therapeutics and 4 mentions for Vir Biotechnology. Relay Therapeutics' average media sentiment score of 0.19 beat Vir Biotechnology's score of 0.13 indicating that Vir Biotechnology is being referred to more favorably in the news media.
Relay Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Relay Therapeutics beats Vir Biotechnology on 11 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
